Rescon Ltd
USPTO PatentsView assignee record - 12 granted patents across 8 technology areas, recorded in grant years 2015–2019. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).
The verdict
According to USPTO PatentsView, Rescon ranks #23,286 of 49,997 tracked US assignees by granted-patent volume, with 12 patents across 8 technology areas.
- #23,286
- of 49,997 US assignees by volume
- 33rd percentile
- by Innovation Score (30.2/100)
- 18.8
- avg claims per patent
- -100%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R23286 · Foreign Corporation #23,286 · 12 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 12 grants
- MID-PACK #23,286/49,997
- PHOTO-FINISH Rehab2fit
- CPC-NARROW A61B · 8 areas
- INNOV-THIN 30.2/100
- CLAIMS-RICH 18.8 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-DROP -100% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Rehab2fit Technologies, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Rescon’s 30.2 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Rescon
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Rescon · this assignee 30
Rescon · this assignee
30 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Rescon's Innovation Score is 30.2/100 (33rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Rescon?
Each dot is one of Rescon’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Rescon’s own 18.8 claims/patent is ABOVE the 17.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Rescon's grants concentrate
Rescon Ltd is a focused PatentsView assignee: 8 CPC subclasses with 75% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2016 (5 grants) versus a trough of 1 in 2019. By volume, Rescon sits between Rehab2fit Technologies, Inc. and Rhodia Acetow GMBH.
Who files at Rescon's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Rehab2fit
Rehab2fit Technologies, Inc.
12 patents
- Reichert
Reichert, Inc.
12 patents
- Reichle & De-mass…
Reichle & De-massari AG
12 patents
- Rentokil Initial…
Rentokil Initial 1927 PLC
12 patents
- Resilient Power S…
Resilient Power Systems, Inc.
12 patents
- Resuscitec
Resuscitec GMBH
12 patents
- Rexahn Pharmaceut…
Rexahn Pharmaceuticals, Inc.
12 patents
- Rhodia Acetow
Rhodia Acetow GMBH
12 patents
- Rescon ◀
Rescon Ltd
12 patents
What this shows Rescon holds 12 patents at rank #23,267, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Rescon
By rank, the assignees closest to #23,267 in granted patent volume.
- Rehab2fit Technologies, Inc. #23,263 · 12 patents
- Reichert, Inc. #23,264 · 12 patents
- Reichle & De-massari AG #23,265 · 12 patents
- Rentokil Initial 1927 PLC #23,266 · 12 patents
- Resilient Power Systems, Inc. #23,268 · 12 patents
- Resuscitec GMBH #23,269 · 12 patents
- Rexahn Pharmaceuticals, Inc. #23,270 · 12 patents
- Rhodia Acetow GMBH #23,271 · 12 patents
Leaders in A61B (Diagnosis)
Other assignees with the most granted patents in Rescon's primary technology class.
- Covidien LP 5,709 in class
- Koniniklijke Philips N.V. 3,414 in class
- Olympus Corporation 2,758 in class
- Boston Scientific Scimed, Inc. 2,362 in class
- Cilag GmbH International 2,063 in class
- Intuitive Surgical Operations, Inc. 1,921 in class
- DePuy Synthes Products, Inc. 1,796 in class
- Ethicon, Inc. 1,762 in class
Rescon's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
30 33rd percentile higher than 33% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 3 | 25.0% |
| 2016 | 5 | 41.7% |
| 2017 | 3 | 25.0% |
| 2019 | 1 | 8.3% |
Which technologies does Rescon Ltd patent most?
Top 8 of 8 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Rescon Ltd's patent record in context - here's where to go next.
- Rescon Ltd's lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 75% of its portfolio - see every assignee active in that class. Explore A61B
- Ranked #23,286 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Rescon Ltd against Rehab2fit Technologies, Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 30.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.